<DOC>
	<DOCNO>NCT00416455</DOCNO>
	<brief_summary>This phase I/II trial study well fludeoxyglucose F 18 PET scan , CT scan , ferumoxtran-10 MRI scan find lymph node metastasis undergo chemotherapy radiation therapy patient locally advanced cervical cancer high-risk endometrial cancer . Diagnostic procedure , fludeoxyglucose F 18 positron emission tomography ( PET ) scan , compute tomography ( CT ) scan , ferumoxtran-10 magnetic resonance imaging ( MRI ) scan , may help find lymph node metastasis patient cervical cancer endometrial cancer .</brief_summary>
	<brief_title>Fludeoxyglucose F 18 PET Scan , CT Scan , Ferumoxtran-10 MRI Scan Before Chemotherapy Radiation Therapy Finding Lymph Node Metastasis Patients With Locally Advanced Cervical Cancer High-Risk Endometrial Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine diagnostic sensitivity specificity preoperative fludeoxyglucose F 18 positron emission tomography ( FDG-PET ) /CT scan ferumoxtran-10 MRI scan identify metastasis abdominal ( common iliac , para-aortic , paracaval ) lymph node patient locoregionally advanced cervical carcinoma . II . Determine diagnostic sensitivity specificity preoperative FDG-PET/CT scan ferumoxtran-10 MRI scan identify metastasis retroperitoneal abdominal lymph node patient high-risk endometrial cancer . SECONDARY OBJECTIVES : I . Determine diagnostic sensitivity specificity preoperative FDG-PET/CT scan ferumoxtran-10 MRI scan identify metastasis pelvic lymph node pelvic abdominal lymph node combine patient locoregionally advanced cervical carcinoma high-risk endometrial cancer . II . Compare additive diagnostic value CT fusion ( PET/CT scan ) v PET scan alone identify metastasis pelvic , abdominal , combine ( region ) lymph nodes patient . III . Compare diagnostic sensitivity specificity PET/CT scan vs ferumoxtran-10 MRI scan identify metastasis pelvic , abdominal , combine lymph node patient . IV . Compare diagnostic sensitivity specificity ferumoxtran-10 MRI v MRI alone , term size criterion abdomen pelvis , patient . V. Determine percentage patient locoregionally advanced cervical cancer high-risk endometrial cancer biopsy-proven disease outside abdominal pelvic lymph node detect PET/CT scan . VI . Determine accuracy MRI determine depth myometrial invasion involvement cervix patient high-risk endometrial cancer . VII . Determine complication associate extraperitoneal laparoscopic abdominal pelvic lymphadenectomy patient locoregionally advanced cervical cancer . VIII . Determine cause ( ) delay initiation radiotherapy interruption radiotherapy patient locoregionally advanced cervical cancer . IX . Collect data adverse effect ferumoxtran-10 patient locoregionally advanced cervical carcinoma high-risk endometrial cancer . X . Compare size lymph node pre- post-ferumoxtran-10 MRI 's subset forty patient . OUTLINE : This multicenter study . Patients receive fludeoxyglucose F 18 ( FDG ) IV follow 60 minute later positron emission tomography ( PET ) /CT scan day 1 . Patients also receive ferumoxtran-10 IV 30-45 minute day 1 ( 24-36 hour MRI ) undergo MRI day 2 . Patients undergo extraperitoneal , laparoscopic , trans-peritoneal lymphadenectomy pelvic abdominal lymph node biopsy within 2 week PET/CT scan . Patients diagnose metastatic disease prior lymph node biopsy proceed directly primary treatment . Patients cervical cancer undergo chemoradiotherapy within 4 week PET/CT scan . After completion study therapy , patient follow 6 week , 6 month , every 3 month 2 year , every 6 month 3 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Cystadenocarcinoma , Serous</mesh_term>
	<mesh_term>Adenomyoepithelioma</mesh_term>
	<mesh_term>Adenocarcinoma , Clear Cell</mesh_term>
	<mesh_term>Carcinoma , Small Cell</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Adenosquamous</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis 1 following : Invasive carcinoma cervix meeting follow criterion : Previously untreated , primary disease Locoregionally advance ( stage IB2 , IIA [ &gt; = 4 cm ] , IIBIVA ) disease Any cell type allow Highrisk endometrial carcinoma meeting 1 follow criterion : Grade 3 endometrioid nonendometrioid endometrial carcinoma ( clear cell serous papillary ) carcinosarcoma diagnose endometrial biopsy dilation curettage Grade 1 2 endometrioid endometrial carcinoma cervical stromal involvement overt clinical examination confirm endocervical curettage Under consideration chemoradiotherapy ( patient cervical cancer ) Undergone appropriate surgery cervical endometrial carcinoma appropriate tissue available histologic evaluation confirm diagnosis stage Appropriate surgical candidate undergo extraperitoneal laparoscopic lymph node sample OR hysterectomy lymph node sample No surgery patient advance lymphadenopathy No recurrent invasive carcinoma uterus uterine cervix regardless previous treatment No known metastasis lung scalene lymph node No metastasis organ outside pelvis abdominal lymph node time original clinical diagnosis Patients endometrial cancer know intraperitoneal disease eligible provide undergo pelvic paraaortic lymphadenectomy per protocol Participants must enrol American College Radiology Imaging Network ( ACRIN ) affiliate institution accredit Gynecologic Oncology Group ( GOG ) GOG performance status 02 Creatinine within normal institutional limit OR , participant creatinine level institutional normal , glomerular filtration rate ( GFR ) must &gt; 60 mL/min ; low limit normal serum creatinine protocol Ferritin level = &lt; 600 ng/mL OR saturation transferrin level = &lt; 50 % Patients high level ferritin transferrin eligible documented hematology rule iron overload Not pregnant nursing Negative pregnancy test No patient weigh great allowable PET/CT scanner No renal abnormality , pelvic kidney , horseshoe kidney , renal transplantation , would require modification lymphadenectomy No history anaphylactic lifethreatening allergic reaction contrast medium No invasive malignancy within past 5 year exception nonmelanoma skin cancer No contraindication MRI ( e.g. , severe claustrophobia , pacemaker , aneurysm clip , defibrillator , institutional contraindication MRI ) No history allergic reaction attribute compound similar chemical biological composition ferumoxtran10 ( e.g. , iron preparation , parenteral iron , parenteral dextran , parenteral irondextran , parenteral ironpolysaccharide preparation ) No immunodeficiency would predispose patient specific nonspecific mediator release No history cirrhosis No poorly control , insulindependent diabetes ( i.e. , fast blood glucose level &gt; 200 mg/dL ) No prior pelvic abdominal lymphadenectomy No prior pelvic radiotherapy No prior anticancer therapy would contraindicate study participation No ferumoxides within past 2 week No investigational agent within past 30 day No concurrent investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>